These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 27733414)

  • 1. Evaluating the safety and dosing of drugs in patients with liver cirrhosis by literature review and expert opinion.
    Weersink RA; Bouma M; Burger DM; Drenth JP; Hunfeld NG; Kranenborg M; Monster-Simons MH; van Putten SA; Metselaar HJ; Taxis K; Borgsteede SD
    BMJ Open; 2016 Oct; 6(10):e012991. PubMed ID: 27733414
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evidence-Based Recommendations to Improve the Safe Use of Drugs in Patients with Liver Cirrhosis.
    Weersink RA; Bouma M; Burger DM; Drenth JPH; Harkes-Idzinga SF; Hunfeld NGM; Metselaar HJ; Monster-Simons MH; Taxis K; Borgsteede SD
    Drug Saf; 2018 Jun; 41(6):603-613. PubMed ID: 29330714
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Review article: prescribing medications in patients with cirrhosis - a practical guide.
    Lewis JH; Stine JG
    Aliment Pharmacol Ther; 2013 Jun; 37(12):1132-56. PubMed ID: 23638982
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Development of Practice Recommendations for Drug-Disease Interactions by Literature Review and Expert Opinion.
    van Tongeren JMZ; Harkes-Idzinga SF; van der Sijs H; Atiqi R; van den Bemt BJF; Draijer LW; Hiel D; Kerremans A; Kremers B; de Leeuw M; Olthoff MV; Pham TK; Valentijn-Robertz R; Tsoi K; Wichers I; de Wit M; Borgsteede SD
    Front Pharmacol; 2020; 11():707. PubMed ID: 32499701
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safe use of medication in patients with cirrhosis: pharmacokinetic and pharmacodynamic considerations.
    Weersink RA; Burger DM; Hayward KL; Taxis K; Drenth JPH; Borgsteede SD
    Expert Opin Drug Metab Toxicol; 2020 Jan; 16(1):45-57. PubMed ID: 31810397
    [No Abstract]   [Full Text] [Related]  

  • 6. Variations of pharmacokinetics of drugs in patients with cirrhosis.
    Pena MA; Horga JF; Zapater P
    Expert Rev Clin Pharmacol; 2016; 9(3):441-58. PubMed ID: 26696448
    [TBL] [Abstract][Full Text] [Related]  

  • 7. NIH Consensus Statement on Management of Hepatitis C: 2002.
    NIH Consens State Sci Statements; 2002 Jun 10-12; 19(3):1-46. PubMed ID: 14768714
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevalence of Drug Prescriptions and Potential Safety in Patients with Cirrhosis: A Retrospective Real-World Study.
    Weersink RA; Taxis K; Drenth JPH; Houben E; Metselaar HJ; Borgsteede SD
    Drug Saf; 2019 Apr; 42(4):539-546. PubMed ID: 30357649
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Safe prescribing in patients with liver cirrhosis; 5 pitfalls].
    Weersink RA; Drenth JPH; Ter Borg F; Mulder MB; Taxis K; Borgsteede SD
    Ned Tijdschr Geneeskd; 2020 Oct; 164():. PubMed ID: 33201633
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antibiotic dosing in cirrhosis.
    Halilovic J; Heintz BH
    Am J Health Syst Pharm; 2014 Oct; 71(19):1621-34. PubMed ID: 25225448
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Procedures and methods of benefit assessments for medicines in Germany.
    Bekkering GE; Kleijnen J
    Eur J Health Econ; 2008 Nov; 9 Suppl 1():5-29. PubMed ID: 18987905
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Guidelines on paediatric dosing on the basis of developmental physiology and pharmacokinetic considerations.
    Bartelink IH; Rademaker CM; Schobben AF; van den Anker JN
    Clin Pharmacokinet; 2006; 45(11):1077-97. PubMed ID: 17048973
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dose adjustment in patients with liver disease.
    Delcò F; Tchambaz L; Schlienger R; Drewe J; Krähenbühl S
    Drug Saf; 2005; 28(6):529-45. PubMed ID: 15924505
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical pharmacokinetic and pharmacodynamic considerations in patients with liver disease. An update.
    Morgan DJ; McLean AJ
    Clin Pharmacokinet; 1995 Nov; 29(5):370-91. PubMed ID: 8582120
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Prescription Pattern of Acetaminophen and Non-Steroidal Anti-Inflammatory Drugs in Patients with Liver Cirrhosis.
    Hong YM; Yoon KT; Heo J; Woo HY; Lim W; An DS; Han JH; Cho M
    J Korean Med Sci; 2016 Oct; 31(10):1604-10. PubMed ID: 27550489
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dose Recommendations for Common Drugs in Patients with Liver Cirrhosis: A Systematic Literature Review.
    Karsten Dafonte K; Weber L; Chmielewski F; Böhmer AM; Lutz P; Hartmann G; Jaehde U; Coenen M
    Clin Drug Investig; 2023 Jul; 43(7):475-502. PubMed ID: 37460783
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Management of drug-disease interactions: a best practice from the Netherlands.
    Diesveld MME; de Klerk S; Cornu P; Strobach D; Taxis K; Borgsteede SD
    Int J Clin Pharm; 2021 Dec; 43(6):1437-1450. PubMed ID: 34273048
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prescribing medications in patients with decompensated liver cirrhosis.
    Amarapurkar DN
    Int J Hepatol; 2011; 2011():519526. PubMed ID: 21994861
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The pharmacotherapy of cirrhosis: concerns and proposed investigations and solutions.
    Hilscher MB; Odell LJ; Myhre LJ; Prokop L; Talwalkar J
    J Clin Pharm Ther; 2016 Dec; 41(6):587-591. PubMed ID: 27576303
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The expert consensus guideline series. Optimizing pharmacologic treatment of psychotic disorders. Introduction: methods, commentary, and summary.
    Kane JM; Leucht S; Carpenter D; Docherty JP;
    J Clin Psychiatry; 2003; 64 Suppl 12():5-19. PubMed ID: 14640142
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.